FDA delays Regeneron Eylea BLA review
Eylea is indicated as a treatment for neovascular age-related macular degeneration (wet AMD). The extension of three months follows the recent amendment made by the company on the
Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).